ИСТИНА |
Войти в систему Регистрация |
|
ИСТИНА ИНХС РАН |
||
The Congress, Co-sponsored by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and Johns Hopkins Medicine, is intended for chemists, physicists, technologists, physicians and all scientists and clinicians interested in translational research and current state-of-the-art molecular imaging using 68Ga PET radiopharmaceuticals and radionuclide therapy. The increase in enthusiasm for 68Ga use over the last several years can be ascribed to several factors, some of which promise an increasing role for 68Ga as a tool in both diagnostic and therapeutic applications such as theranostics. The term "theranostics" symbolizes the inseparability of diagnosis and therapy and has a profound effect personalized disease management. Click here to download the Congress Flyer. Although widely used in Europe, 68Ga PET radiopharmaceuticals have only been used in the US in investigational trials under INDs. With the potential of an approved agent available in the US in the near future, this conference is particularly useful to those who are new to this class of agent and want to hear more about it. A team of experts from around the world present their research and discuss updates in this exciting and evolving field. Presentations on clinical applications and patient advocacy are new to this Congress, providing a unique perspective for attendees.